Margolius H S, Chao J
J Clin Invest. 1980 Jun;65(6):1343-50. doi: 10.1172/JCI109798.
Renal kallikrein is localized in luminal plasma membranes of the mammalian distal nephron and gains access to urine from this site. Its activity is regulated, in part, by aldosterone. These facts led us to study the effects of amiloride, a drug known to inhibit sodium reabsorption and potassium secretion at this site, on kallikrein activity. Amiloride inhibited the esterolytic activity of purified rat or human urinary kallikrein or of rat renal cortical cells upon a synthetic substrate (ID50 = 0.12-0.23 mM). Kinetic analyses showed that the enzyme inhibition was noncompetitive and reversible in nature. The kinin-generating activity of kallikrein acting upon kininogen substrates was also inhibited by amiloride, as measured by bioassay in the rat uterus of guinea pig ileum or by radioimmunoassay of liberated kinins (ID50 = 85 microM). No other diuretic drug tested inhibited kallikrein activity, except triamterene, which did so, weakly. In addition, kallikrein-like enzyme activity was discovered in the urinary bladder or skin of Bufo marinus toads and this activity was also inhibited by amiloride. The localization of the enzyme and its inhibition by this drug suggest that further study of relationships amongst the glandular kallikrein-kinen system and renal ion and water transport is warranted.
肾激肽释放酶定位于哺乳动物远端肾单位的管腔质膜中,并从该部位进入尿液。其活性部分受醛固酮调节。这些事实促使我们研究氨氯地平(一种已知可抑制该部位钠重吸收和钾分泌的药物)对激肽释放酶活性的影响。氨氯地平抑制纯化的大鼠或人尿激肽释放酶或大鼠肾皮质细胞对合成底物的酯解活性(半数抑制浓度 = 0.12 - 0.23 mM)。动力学分析表明,该酶抑制作用本质上是非竞争性且可逆的。通过在大鼠子宫或豚鼠回肠中进行生物测定或通过对释放的激肽进行放射免疫测定,发现氨氯地平也抑制激肽释放酶作用于激肽原底物的激肽生成活性(半数抑制浓度 = 85 μM)。除了作用较弱的氨苯蝶啶外,所测试的其他利尿药均未抑制激肽释放酶活性。此外,在海蟾蜍的膀胱或皮肤中发现了类激肽释放酶活性,并且该活性也受氨氯地平抑制。该酶的定位及其受该药物的抑制表明,有必要进一步研究腺体激肽释放酶 - 激肽系统与肾离子和水转运之间的关系。